Jimmy Fund Press Releases

Mark Pomerantz, MD, recently shared the latest in prostate cancer research and treatment.

In a span of five weeks, the FDA gave approval to five new cancer drugs that proved effective in Dana-Farber-led clinical trials.

The year 2015 marked a milestone in the treatment of lung cancer, with two new immunotherapy drugs approved for patients with advanced disease.

The Pan-Mass Challenge (PMC) announced a gift of $45 million to support adult and pediatric patient care and cancer research at Dana-Farber Cancer Institute.

New research reveals cancer therapy that works by converting a tumor's best friends in the immune system into its gravest enemies.

A new drug slowed the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had previously kept it in check.

Rock legend James Taylor will headline Dana-Farber’s Discovery Celebration Feb. 20, 2016. Join us for the 25th Anniversary events in Palm Beach, FL.

The 2015 WEEI/NESN Jimmy Fund Radio-Telethon presented by Arbella Insurance Foundation raises more than $3.4 million in 36-hour broadcast.

Childhood cancer and the promise of gene therapy - gaining traction on a powerful technique for correcting mistakes (mutations) in DNA of human cells.

Drinking coffee daily may improve survival in colon cancer patients, according to a new study.

WEEI Sports Radio Network (93.7 FM), NESN and the Boston Red Sox are proud to announce that the 14th annual WEEI/NESN Jimmy Fund Radio-Telethon presented by Arbella Insurance Foundation will take place at Fenway Park on Tuesday, August 18 and Wednesday, August 19, from 6 a.m. to midnight.

Men with metastatic, hormone-sensitive prostate cancer gained more than a year of survival when they received both hormone-blocking medications and chemotherapy right after diagnosis.

A study led by Dr. Alexi Wright finds intraperitoneal chemotherapy substantially improves survival of ovarian cancer patients.

Dana-Farber/Brigham and Women's Cancer Center has been named the best for cancer care in New England for the 15th straight year and fourth overall in the country by U.S. News & World Report.

Dana-Farber Cancer Institute and Eli Lilly and Company announced a multiyear collaboration to research new medicines under development to fight cancer.

A social media campaign focusing on sharing jokes and pledging money to the Jimmy Fund is the grand prize winner of the Jimmy Fund Big Ideas Contest. “Jimmy Fund Jokers: Laughter is the Best Medicine,” is the idea submitted by the Surprenant Family of Needham, MA.

Dana-Farber/Boston Children’s Cancer and Blood Disorders Center remains the nation’s top pediatric cancer program, according to the 2015-16 edition of U.S. News & World Report’s Best Children’s Hospitals.

Dana-Farber's Molecular Cancer Imaging Facility will use cutting edge technology for research on improving cancer diagnosis and developing precision drugs.

Immunotherapy, targeted drugs, brain cancer research among highlights at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO).

A new technology may make it possible to target "undruggable" proteins and overcome drug resistance by using a cancer cell's own protein-degrading machinery.

Dana-Farber's Levi Garraway, MD, PhD, has been selected as one of 26 Howard Hughes Medical Institute investigators.

A new drug combination boosts survival in advanced stomach and esophageal cancer.

A new drug combination lengthened the lives of patients with metastatic colorectal cancer, all of whom had exhausted available standard treatments.

Dr. Lawrence Shulman led the effort to add sixteen drugs to the World Health Organization’s List of Essential Medicines.

Men taking statin drugs to lower cholesterol when they started hormone therapy for prostate cancer held their cancer at bay for 10 months longer in a Dana-Farber study.

Almost as long as scientists have known of the existence of viruses, they’ve dreamed of using them against cancer. Now, science is giving substance to the dream.

Even before President Barack Obama declared it a national initiative, precision medicine has helped bring more treatment to patients with many types of cancer.

Excitement about immunotherapy treatments for cancer continued at the 2015 meeting of the AACR, one of the largest cancer research meetings of the year.

Dana-Farber's Alan D'Andrea, MD, has been selected to lead a Stand Up To Cancer Dream Team devoted to ovarian cancer research.

Shonda Schilling, wife of World Series Champion Boston Red Sox retired pitcher Curt Schilling, is running the Boston Marathon on the Dana-Farber team.

After what looked like a scientific dead end, a group of Dana-Farber scientists discovered a distinct genetic subtype of acute myeloid leukemia (AML).

Boston Red Sox third basemen Brock Holt and Pablo Sandoval will serve as Jimmy Fund Co-Captains for the 2015 baseball season.

The Jimmy Fund Big Ideas Contest launched today, seeking the public’s ideas for a new fundraiser to benefit cancer research and patient care at Dana-Farber Cancer Institute, one of the country’s leading cancer institutions.

Dana-Farber has created a four-part, web-based oral chemotherapy animated video series to help educate cancer patients about oral chemotherapy.

By measuring how vigorously tumor cells turn on "self-destruct" signals, a new lab test can quickly predict which cancer drug is most likely to work.

What is precision or "personalized" medicine? Dana-Farber experts share five things you should know about precision medicine.

Scientists have published the first comprehensive catalog of genetic mutations and other abnormal changes found in 279 cancers of the head and neck.

Dana-Farber Cancer Institute is expanding its research footprint, occupying portions of five floors at Longwood Center.

'Orange Is the New Black' star Uzo Aduba will run the 2015 Boston Marathon® to support Dana-Farber Cancer Institute.

A new study shows high vitamin D levels increases survival of patients with metastatic colorectal cancer.

Women with small, HER2-positive breast tumors who received combination treatment were highly unlikely to have the cancer recur within three years.